Video

Jason R. Gotlib Discusses MPN Research at Stanford

Author(s):

Jason R. Gotlib

Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Jason R. Gotlib, Associate Professor of Medicine (Hematology) at the Stanford University Medical Center, discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Recognized for advancing the science of MPNs, Dr. Gotlib is the Principal Investigator for a number of clinical trials in the classic MPNs, and for a database registry specifically for MPN research. In addition, he is acclaimed for his leadership in professional and patient education conferences. Besides mentoring medical fellows and serving as the Editor-in-Chief of The Hematologist, Gotlib is highly regarded by his patients for his dedication and sincerity

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Related Content
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis: © stock.adobe.com
April 19th 2025

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

Alex Biese
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of blood cells.
March 16th 2025

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

Spencer Feldman
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
March 6th 2025

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Ryan Scott
Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.